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Dyskeratosis congenita (DC) is a pediatric bone marrow failure syndrome caused by
germline mutations in telomere biology genes. Mutations in DKC1 (the most commonly
mutated gene in DC), the 39 region of TERC, and poly(A)-specific ribonuclease (PARN)
cause reduced levels of the telomerase RNA component (TERC) by reducing its stability
and accelerating TERC degradation. We have previously shown that depleting wild-type
DKC1 levels by RNA interference or expression of the disease-associated A353V mutation
in the DKC1 gene leads to decay of TERC, modulated by 39-end oligoadenylation by
noncanonical poly(A) polymerase 5 (PAPD5) followed by 39 to 59 degradation by
EXOSC10. Furthermore, the constitutive genetic silencing of PAPD5 is sufficient to rescue
TERC levels, restore telomerase function, and elongate telomeres in DKC1_A353V mutant
human embryonic stem cells (hESCs). Here, we tested a novel PAPD5/7 inhibitor
(RG7834), which was originally discovered in screens against hepatitis B viral loads in
hepatic cells. We found that treatment with RG7834 rescues TERC levels, restores
correct telomerase localization in DKC1 and PARN-depleted cells, and is sufficient to
elongate telomeres in DKC1_A353V hESCs. Finally, treatment with RG7834 significantly
improved definitive hematopoietic potential from DKC1_A353V hESCs, indicating that
the chemical inhibition of PAPD5 is a potential therapy for patients with DC and reduced
TERC levels.
Introduction
Dyskeratosis congenita (DC) is characterized by a classic triad of dysplastic nails, lacy reticular
pigmentation of the upper chest and neck, and oral leukoplakia.1 Patients with DC present at early age
with short telomeres, and bone marrow failure represents the major cause of morbidity.2 Treatment is
challenging and tailored to the individual.3 Hematopoietic stem cell transplantation remains the only
curative treatment of bone marrow failure in these patients but historically has had poor long-term
efficacy.4 Novel alternatives for clinical management are urgently needed.
Mutations in patients with DC are found in different genes involved in telomere protection or
maintenance.5,6 Four of these genes impair the function of the telomerase RNA component TERC
leading to reduced telomerase activity, including mutations in TERC itself, poly(A)-specific ribonuclease
(PARN),7-9 NAF1,10 and DKC1,11,12 which represents the most commonly mutated gene in DC
(X-linked inheritance). Mutations in PARN and DKC1 reduce TERC stability and cause increased TERC
degradation by the exosome component EXOSC10.13,14 We and others have shown that the
degradation of TERC by the exosome can be inhibited by reducing the 39-end oligoadenylation of TERC
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through the modulation of PAPD5 [noncanonical poly(A) poly-
merase 5] levels.13-17 Utilizing the targeted differentiation of human
embryonic stem cells (hESCs), we showed that the genetic
silencing of PAPD5 is able to improve the hematopoietic poten-
tial of DC cells,18 thereby rescuing the major phenotype ob-
served in this disease. This finding opens the possibility that the
chemical inhibition of PAPD5 by a safe, efficient, orally available
compound could represent a novel alternative to be pursued in
the clinical management of patients with DC and mutations that
impair TERC biology.
Herein, we show that treatment of PARN- or DKC1-depleted
cells with RG7834, a novel small molecule inhibitor of PAPD5
and PAPD7,19,20 leads to increased TERC levels and correct
telomerase RNA subcellular localization. Moreover, RG7834
treatment significantly decreased the 39-end oligoadenylation of
TERC in DKC1_A353V hESCs, leading to increased TERC
levels in these cells. The chemical inhibition of PAPD5/7 was
sufficient to elongate telomeres in DKC1_A353V hESCs and to
significantly improve the definitive hematopoietic potential of












































































































































Figure 1. RG7834 treatment rescues TERC levels and localization in DKC1- and PARN-depleted cells. (A) Representative northern blots for TERC levels in HeLa
cells under indicated conditions. Numbers below panels: average 6 standard deviation for 3 biological replicates. (B) Quantification of TERC by quantitative reverse
transcription polymerase chain reaction in HeLa cells under the indicated conditions (n 5 3; biological replicates). Values are expressed in relation to scrambled control.
(C) Representative images for 49,6-diamidino-2-phenylindole (DAPI) (nucleus), coilin (cajal body), TERC, and merge of individual channels obtained from HeLa cells transfected
with indicated siRNAs and treated with RG7834. White arrows indicate TERC localization within the cell. Scale bar, 5 mm. Numbers in image panels: Quantification of fraction
of cells with TERC colocalized to cajal bodies from at least 30 independent cells and 3 replicates. Cells with at least one TERC focus colocalized with coilin were counted.
(D) Telomerase activity by telomere repeat amplification in HeLa cells transfected with indicated siRNAs and treated with 5 mM of RG7834 or DMSO. Range of protein
concentrations represent fourfold serial dilutions. *P , .05; **P , .01. LC, loading control.
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modulation of PAPD5 activity could serve as a potential novel
therapy for patients with DC.
Methods
Wild-type (WT) (WA01) and DKC1_A353V mutant hESCs were
maintained as previously described.21 RG7834 was acquired from
MedKoo Biosciences (Morrisville, NC) and diluted in dimethyl sulf-
oxide (DMSO) (MilliporeSigma, Burlington, MA). Detailed methods
and experimental procedures are described in the supplemental
Methods.
Results and discussion
To investigate whether RG7834 treatment phenocopies PAPD5
knockdown, we depleted DKC1 in HeLa cells (supplemental Figure
1A-B) and treated them with either DMSO (control) or 5 mM of
RG7834 for 2 days. Similar to previous results,13 knockdown of
DKC1 led to a significant reduction in TERC levels (Figure 1A-B).
Importantly, treatment with RG7834 led to a significant increase in
TERC levels in DKC1 knockdown cells, indicating that RG7834 is
able to increase TERC levels in DKC1-deficient cells. Because the
depletion of PARN also leads to TERC degradation mediated by 39
end adenylation by PAPD5,13 we silenced PARN in HeLa cells and
treated them with DMSO or 5 mM of RG7834 for 2 days. We found
that PARN knockdown leads to a significant reduction in TERC
levels, which is completely rescued by RG7834 treatment. Thus,
similar to the genetic silencing of PAPD5, treatment with RG7834
increased TERC levels in both PARN- and DKC1-deficient cells,
without affecting levels of either DKC1 or PARN in individual
knockdown cells. Finally, RG7834 treatment did not affect TERC
levels in HeLa cells that were not subject to silencing of either
DKC1 or PARN (supplemental Figure 1C).
We have previously shown that in DKC1- or PARN-depleted cells,
TERC accumulates in cytoplasmic puncta called “cyTER bodies,”13
instead of its normal localization to cajal bodies in the nucleus.22,23
To investigate whether RG7834 treatment rescued TERC locali-
zation to cajal bodies in the nucleus, we treated DKC1- or PARN-
depleted cells with RG7834 for 2 days. We found that in WT
control cells, TERC localized to cajal bodies, suggesting normal
accumulation and trafficking of the telomerase RNA component
(Figure 1C). However, in control DKC1 knockdown cells, only
;15% of cells showed TERC localization to cajal bodies, with a
significant number of cells exhibiting TERC accumulation in cyTER
bodies. Upon treatment with RG7834, ;38% of cells had TERC
localized to cajal bodies, which is consistent with the 1.53 increase
in TERC levels in these cells. RG7834 treatment also rescued
TERC localization to cajal bodies in PARN-depleted cells. In PARN
knockdown cells, ;34% of cells had TERC in cajal bodies, with
TERC also mostly being localized to cyTER bodies in these cells.
However, upon RG7834 treatment, ;85% of cells had TERC
localized to cajal bodies. Finally, treatment with RG7834 was also
able to increase telomerase activity in DKC1- and PARN-depleted
cells (detected by using 2-step telomere repeat amplification
assays) (Figure 1D; supplemental Figure 1D), which is consistent
with the increase in TERC levels (Figure 1A-B). No toxicity was
observed in RG7834-treated cells for the duration of these
experiments. Taken together, these results suggest that the
chemical inhibition of RG7834 is effective at increasing TERC
levels, correcting TERC localization to cajal bodies, and in-
creasing telomerase activity in DKC1- or PARN-depleted cells,
indicating restored telomerase function in these conditions.
We next investigated whether RG7834 exhibits a similar effect on
TERC levels and function in a physiologically relevant model of
DC. We have previously generated (through CRISPR/Cas9 gene
editing) DKC1_A353V mutant hESCs, which exhibit reduced
TERC levels and telomerase activity, progressive telomere short-
ening, and impaired definitive hematopoietic specification.21 Treat-
ment of DKC1_A353V hESCs with RG7834 caused a .15-fold
reduction in the 39-end oligoadenylation of TERC, indicating effi-
cient PAPD5 inhibition in these cells (Figure 2A). Inhibition of 39 end
oligoadenylation led to a significant increase in TERC levels in
DKC1_A353V hESCs (4 days of treatment) (supplemental Figure 2A),
which was sustained up to 30 days upon continuous treatment with
different concentrations of RG7834 (Figure 2B). Although the levels of
the telomerase reverse transcriptase (TERT) remained unchanged
during this period, the increased TERC levels found in DKC1_A353V
hESCs treated with RG7834 caused a noticeable rise in telomerase
activity in DKC1_A353V hESCS treated with different concentrations
of the PAPD5/7 inhibitor (Figure 2C; quantification in supplemental
Figure 2B).
The sustained treatment (up to 3 months) with RG7834 also led to
improved telomere maintenance, analyzed by telomere restriction
fragment analysis, in DKC1_A353V hESCs (Figure 2D). Together,
these data suggest that RG7834 treatment rescued TERC levels,
prevented its 39 end oligoadenylation, increased telomerase activity,
and improved telomere homeostasis in DKC1_A353V hESCs.
Finally, we investigated if treatment with RG7834 was sufficient to
reduce DNA damage signaling arising from eroded telomeres, a
hallmark of DC. We observed that gH2AX levels were reduced in
DKC1_A353V cells treated with different concentrations of RG7834
compared with DMSO-treated cells (supplemental Figure 3A).
Importantly, we detected no toxicity associated with RG7834
Figure 2. RG7834 treatment rescues telomerase activity, increases telomere length, and improves hematopoietic specification in DKC1_A353V mutant
hESCs. (A) Quantification of oligo(A) reads at the 39 end (UGC) of TERC in indicated conditions (average 6 standard deviation from 2 independent replicates). TERC reads
with more than 2 As at the 39 end are considered oligoadenylated. (B) Quantification of TERC and TERT by quantitative reverse transcription polymerase chain reaction in
DKC1_A353V hESCs treated with DMSO or different concentrations of RG7834 for 30 days (n 5 3; biological replicates). (C) Telomerase activity by telomere repeat
amplification in DKC1_A353V hESCs treated with DMSO or different concentrations of RG7834. Range of protein concentrations represent fourfold serial dilutions.
(D) Telomere length analysis by telomere restriction fragment analysis of DKC1_A353V hESCs treated with DMSO or different concentrations of RG7834 for 90 days.
(E) Representative flow cytometric analysis of CD34 and CD43 expression on day 8 of definitive hematopoietic differentiation, following CHIR99021 and SB-431542 treatment
in DKC1_A353V cells treated with DMSO or different concentrations of RG7834. (F) Quantification of CD341CD43– population obtained from day 8 differentiation cultures
treated with CHIR99021 and SB-431542, as in panel E. (G) CFC potential of definitive hematopoietic progenitors in WT and DKC1_A353V cells treated with DMSO or 1mM
of RG7834 (n 5 3; biological replicates). Statistical significance was determined by using one- or two-way analysis of variance following a Bonferroni multiple comparison
posttest. *P , .05; **P , .01; ***P , .001. BFU-E, burst forming unit-erythroid; CFC, colony forming cell; MTL, mean telomere length; n.s., not significant.
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treatment at the concentrations indicated, during the entire duration
of the experiments performed (supplemental Figure 3B-C). In addi-
tion, whole-genome RNA-sequencing analysis showed that treat-
ment with 1 mM of RG7834 did not lead to significant changes in
gene expression in DKC1_A353V mutant hESCs compared with
DMSO-treated cells (supplemental Figure 3D), suggesting that
RG7834 treatment affects specific RNAs in hESCs and rules out
toxicity associated with genome-wide gene expression perturba-
tions. Combined, these data indicate that similar to the genetic
silencing of PAPD5, treatment with RG7834 is able to rescue the
major biochemical phenotypes observed in DC models.
Finally, because bone marrow failure is the leading cause of death in
DC, we wanted to analyze the consequences of RG7834 treatment
in DKC1_A353V cells during definitive hematopoietic differentia-
tion. There are no animal models that faithfully recapitulate the
hematopoietic defects observed in patients harboring pathogenic
mutations in DKC1 or PARN; we therefore followed established
protocols of hESC differentiation into hematopoietic lineages.
These protocols recapitulate, in vitro, the major aspects of blood
development in vivo,24 a strategy that we and others have shown to
accurately model key aspects of DC.18,21,25,26 A schematic of our
protocol is depicted in supplemental Figure 4. Our data show that
although CD341CD43– early hematopoietic progenitors (day 8 of
differentiation) (Figure 2E-F) were similar in all samples, definitive
hematopoietic colony potential analysis (day 28 of differentiation)
revealed that treatment with different concentrations of RG7834
significantly increased the hematopoietic potential of DKC1_A353V
cells (Figure 2G). These observations provide compelling evidence
that chemical inhibition of PAPD5, in addition to rescuing telomerase
function, is sufficient to increase definitive, multilineage, hematopoi-
etic potential in DKC1_A353V mutants.
Our data provide functional evidence that a small molecule inhibitor
of PAPD5/7 significantly increases TERC levels, localization, and
function in DKC1- and PARN-deficient cells. We show that RG7834
reduces the 39-end oligoadenylation of TERC, increases TERC levels
and telomerase activity, and elongates telomeres in PARN- or DKC1-
deficient cells. RG7834 treatment was sufficient to restore the in vitro
definitive hematopoietic development of DKC1_A353V hESCs, sim-
ilarly to what we have recently observed with the genetic silencing of
PAPD5.18 Although these experiments represent the first nongenetic
rescue of hematopoietic development from hESCs in DKC1 mutant
cells, it has recently been shown that PAPD5 inhibitors are able
to promote telomere restoration in different patient-derived DC
samples in vitro and in vivo, through xenotransplantation assays27;
these results provide further support for the future use of this
technology in the clinic. In addition, the studies presented here
indicate that small increases in TERC levels (less than twofold) are
sufficient to increase telomerase activity and improve hematopoietic
output in DKC1 mutant cells. Future experiments performed in cells
harboring mutations in other genes that impair TERC levels/function
(including TERC itself, NHP2, NOP10, and ZCCHC8) are necessary
for determining the scope and range of effectiveness of PAPD5
inhibition for DC treatment. In addition, the efficiency of PAPD5
inhibition to ameliorate other phenotypes that are commonly
associated with telomere shortening, such as pulmonary fibrosis
and liver disease, must be assessed, as these conditions cause
substantial morbidity and mortality and represent an important
unmet need for these patients. Nonetheless, the experiments
presented here indicate that the chemical inhibition of PAPD5
by RG7834 or other specific small molecule inhibitors can be
a promising therapeutic approach for the treatment of DC or
other telomere biology syndromes caused by mutations that reduce
TERC levels.
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